NovaUCD-based medtech OncoAssure has announced the launch of its OncoAssure Prostate Test in the US market, as well as plans to hold an investment round last year.
The next-generation prognostic test is designed to support clinical decision-making for men diagnosed with localised prostate cancer, and helps to assess the risk of aggressive disease and disease recurrence.
It can be used at two key decision points in the prostate cancer pathway, post-biopsy and post-surgery.
By integrating advanced genomic insights with clinical data, OncoAssure Prostate provides a more accurate assessment of disease prognosis, allowing doctors to make more precise and personalised treatment decisions.
The company made the announcement at the American Urological Association’s (AUA) 2025 Annual Meeting, which is taking place in Las Vegas, Nevada.
"This launch represents a major milestone in the commercialisation of the test in the US market,” said Desmond O’Leary, CEO of OncoAssure.
"Access to prognostic testing remains limited for many patients in the US, making the launch of OncoAssure Prostate especially timely.
"This test addresses a critical need by providing reliable information to distinguish between aggressive and low-risk forms of prostate cancer, helping to reduce overtreatment and improve patient outcomes.”
The OncoAssure Prostate Test is being commercialised in the US in collaboration with DiaCarta Inc., which will provide the testing service from its ISO and CAP/CLIA certified laboratory service in Pleasanton, California.
The OncoAssure Prostate Test was developed using the innovative OncoAssure Process, through which a concise panel of upstream 'Master Driver' genes that represent a reliable indicator of disease progression were identified.
The OncoAssure Prostate test also incorporates the widely used Cancer of the Prostate Risk Assessment (CAPRA) score in the result, allowing seamless integration into current care pathways.
"Through the OncoAssure product development process we've successfully delivered our next-generation prognostic test. Building on this momentum, we've made strong progress in developing our next product, a prognostic test for skin melanoma," said O'Leary.
OncoAssure was co-founded by O’Leary and Prof. William Gallagher in 2021, and the planned funding round will fund the ongoing commercialisation of OncoAssure Prostate as well as the development of novel cancer biomarkers.

The company had current assets of €815,000, including cash reserves of €526,700, and net assets of €87,100 at the end of February 2024, according to the latest available accounts.
Photo: Pictured at NovaUCD in Dublin is Des O'Leary, CEO and co-founder, OncoAssure. (Pic: Vincent Hoban, UCD)